RET and non-small cell lung carcinoma: The LIBRETTO-001 phase 1/2 trial (NCT03157128) was instrumental in unveiling the efficacy of selpercatinib in managing RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC), paving the way for its initial regulatory approvals1,2.